A novel series of N-(hexahydro-1,4-diazepin-6-yl) and N-(hexahydroazepin-3-yl)benzamides with high affinity for 5-HT3 and dopamine D2 receptors

Bioorganic and Medicinal Chemistry Letters

Volumn 8, Issue 6, 1998, Pages 619-624

  Hirokawa, Yoshimi ^a   Morie, Toshiya ^a   Yamazaki, Hiroshi ^a   Yoshida, Naoyuki ^a   Kato, Shiro ^a  

^a DAINIPPON SUMITOMO PHARMA CO LTD   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

3 (5 METHYL 1H IMIDAZOL 4 YL) 1 (1 METHYL 1H INDOL 3 YL) 1 PROPANONE; BENZAMIDE DERIVATIVE; DOMPERIDONE; DOPAMINE 2 RECEPTOR; METOCLOPRAMIDE; ONDANSETRON; SEROTONIN 3 RECEPTOR;

ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; BRAIN CORTEX; CORPUS STRIATUM; DRUG RECEPTOR BINDING; DRUG SYNTHESIS; ENANTIOMER; NONHUMAN; RAT; RECEPTOR AFFINITY; STRUCTURE ACTIVITY RELATION;

ANIMALS; BENZAMIDES; BINDING SITES; CEREBRAL CORTEX; CORPUS STRIATUM; DOMPERIDONE; DOPAMINE ANTAGONISTS; IMIDAZOLES; INDOLES; LIGANDS; METOCLOPRAMIDE; MODELS, CHEMICAL; ONDANSETRON; RATS; RECEPTORS, DOPAMINE D2; RECEPTORS, SEROTONIN; RECEPTORS, SEROTONIN, 5-HT3; SEROTONIN ANTAGONISTS; SPIPERONE; STEREOISOMERISM;

ANIMALIA;

EID: 0032539786     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-894X(98)00078-X     Document Type: Article

References (22)

1. 1. Harrington, R. A.; Hamilton, C. W.; Brogden, R. N.; Linkewich, J. A.; Romankiewicz, J. A.; Heel, R. C. Drugs, 1983, 25, 451-494.
2. 2. McRitchie, B.; McClelland, C. M.; Cooper, S. M.; Turner, D. H.; Sanger, G. J. In Mechanisms of Gastrointestinal Motility and Secretion; Bennett, A.; Velo, G. P. Eds., Plenum Press, New York, 1984; pp. 287-302.
3. 3. a) Leibundgut, U.; Lancranjan, I. Lancet, 1987, 1, 1198;
4. b) Cunningham, P.; Pople, A.; Ford, H. T.; Hawthorn, J.; Gazet, J. C.; Challoner, T. ibid., 1987, 1, 1461-1462;
5. c) Andrew, P. L. R.; Rapeport, W. G.; Sanger, G. J. Trends Pharmcol. Sci., 1988, 9, 334-341.
6. 4. a) Reyntjens, A.; Verlinden, M.; Aerts, T. Drug Dev. Res., 1986, 8, 251-265;
7. b) Müller-Lissner, S. A. Gastroenterology, 1985, 88, 1510-1516:
8. c) Müller-Lissner, S. A. Gut, 1987, 28, 1033-1038;
9. d) McCallum, R. W.; Prakash, C.; Campoli-Richards, D. M.; Goa, K. L. Drugs, 1988, 36, 652-681.
10. 5. a) Brogden, R. N.; Carmine, A. A.; Heel, R. C.; Speight, T. H.; Avery, G. S. Drugs, 1982, 24, 360-400;
11. b) Davis, R. H.; Clench, M. H.; Mathiae, J. R. Dig. Dis. Sci., 1988, 33, 1505-1511.
12. 6. Triozzi, P. L.; Laszlo, J. Drugs, 1987, 34, 136-149.
13. 7. Harada, H.; Morie, T.; Hirokawa, Y.; Yoshida, N.; Kato, S. Chem. Pharm. Bull., 1995, 43, 1364-1378.
14. 8. Morie, T.; Harada, H.; Hirokawa, Y.; Kato, S. Chem. Pharm. Bull., 1996, 44, 2205-2212.
15. 9. Kato, S.; Harada, H.; Morie, T. J. Chem. Soc., Perkin Trans. 1, 1997, 3219-3225.
16. 10. a) Pellegate, R.; Pinza, M.; Pifferi, G. Synthesis, 1978, 614-616;
17. b) Boyle, Jr., W. J.; Sifniades, S.; Van Peppen, J. F. J. Org. Chem., 1979, 44, 4841-4847.
18. 11. Kilpatrick, G. J.; Jones, B. J.; Tyers, M. B. Eur. J. Pharmacol., 1989, 159, 157-164.
19. 12. List, S. J.; Seeman, P. Proc. Natl. Acad. Sci. USA, 1981, 78, 2620-2624.
20. 50; 1.4 μg/kg, iv), respectively, were examined.
21. 14. Fozard, J. R.; Host, M. Br. J. Pharmacol., 1982, 77, 520.
22. 15. Janssen, P. A. J.; Niemegeers, C. J. E.; Schellekens, K. H. L. Arzneim.-Forsch., 1965, 15, 1196-1206.